Agenda

8:00 am Registration and Welcome Coffee

8:30 am Chair’s Opening Remarks

Keynote Panels

8:40 am Panel: One Vision for the Future of Oncolytic Virotherapies

Synopsis

• The next generation of OV therapies – combination therapy or modified mono-therapy?
• Consider the role of transgenes and checkpoint inhibitors
• Look to possible indications beyond cancer – are virotherapy drugs translatable to other gene therapies?

9:20 am Panel: To IT or to IV? Intra-Tumoural vs Intra-Venous Administration

Synopsis

• Decide whether OV treatments are most effective when injected directly into the tumour or systemically
• Weigh the risks of IT administration with the benefits of a more targeted approach
• Consider the views of physician

10:00 am Speed Networking

Synopsis

Establish meaningful business connections at a rapid rate. Efficiency at its finest.

11:00 am Morning Networking Break

The Latest Advances in Research

11:30 am Case Study: Comparative Oncology in Domesticated Canines and Humans

Synopsis

  • Translate efficacious canine read-outs to human patients
  • Systemic infiltration to target cancer regardless of tumour micro-environment through IV administration and up-regulation of receptors in the tumour
  • Creation of an effective mono-therapy through the use of transgenes making the requirement of combination therapies with checkpoint inhibitors obsolete

11:50 am Case Study: Considerations When Using Vaccinia Virus as a Vector for Oncolytic Vaccines

  • Sridhar Pennathur Senior Director and Fellow Biopharmaceutical Development, AstraZeneca

Synopsis

·  Harnessing the potent immune response of the Pox Virus

·  Inserting genes into complex viruses

·  Purification and safety testing on a commercial scale

12:10 pm Case Study: The Benefits of Monotherapies and Combination Based on Disease Indication

Synopsis

· Creation of an effective monotherapy through the use of transgenes

·  ONCR-177 express PD-1 and CTLA4 antagonists data supporting monotherapy benefits and combination with ICI in varying indications

12:30 pm Q&A Panel

Synopsis

The audience take the mic (and control) with questions for our speakers

12:30 pm Q&A Panel

Synopsis

The audience take the mic (and control) with questions for our speakers

1:00 pm Lunch Networking Break

The Latest Advances in Research

2:00 pm Case Study: Proprietary I23 armed oncolytic

Synopsis

·  Target stromal based cancers, including ovarian and lung, via systemic administration by including genetically engineered antibodies in the OV

·  Modify the viral vector to tailor to specific disease indications

·  Amend the virus to use as a monotherapy in cancers which cannot tolerate checkpoint inhibitors such as ovarian cancer

2:20 pm Targovax’s ONCOS-102 in the Treatment of PD-1 Refractory Melanoma

Synopsis

·  Phase I ORR and immune data

·  Combination with KEYTRUDA checkpoint inhibitor

2:40 pm OncoMyx’s Systemic Administration of EV2

Synopsis

·  Pox virus platform with large Genome for easy transgene modification

·  Solid tumour focus across indications

3:00 pm Pharmico-dynamic non-invasive monitoring techniques

Synopsis

– Real-time tracking and improved visibility of viruses post-administration
– Utilization of medical imaging and soluble markets secreted by the virus to maintain insight into the effects of the virus

3:20 pm Q&A Panel

Synopsis

The audience take the mic (and control) with questions for our speakers

3:40 pm Afternoon Networking Break

4:10 pm Panel: Viral Vehicle Comparison

  • David Sherris President and Chief Executive Officer, GenAdam Therapeutics Inc.
  • Sridhar Pennathur Senior Director and Fellow Biopharmaceutical Development, AstraZeneca
  • Shara Dellatore Principal Scientist and Group Leader, Merck

Synopsis

·  Target specific tumour microenvironments by identifying the most effective virus

·  Consider the size of the virus and the limitations of the level of DNA that can be infused with it

·  Decide whether viruses are the best vector for the novel genes needed to create an effective immuno-oncology therapy

4:50 pm Speed Learning

Synopsis

Roundtable discussions like you’ve never seen them before.

Uncover the story behind four fibrotic therapeutic developments in one quick-fire session. Each table will be hosted by leading specialist who will share the secrets of their most high-impact strategy; you then get the opportunity to question the host before moving on to your next table.

5:50 pm Poster Session and Drinks Reception